HDL: Fact,fiction,or function? HDL cholesterol and cardiovascular risk

Abstract

The measurement of high-density lipoprotein cholesterol is highly utilized by clinicians to help predict cardiovascular risk, but this measure is not causally associated with atherosclerotic cardiovascular disease events. The use of Mendelian randomization studies has led to a change in investigative attention from the high-density lipoprotein cholesterol concentration to its physiological functions. High-density lipoprotein plays key roles in important pathways related to the development of atherosclerotic disease including reverse cholesterol transport, oxidation and inflammation, and endothelial function as well as in other physiological systems including immune system modulation, cellular apoptosis, and endothelial progenitor cell homeostasis. The identification of dysfunctional high-density lipoprotein may better predict future cardiovascular events compared to numerical high-density lipoprotein cholesterol and aid in enhanced clinical risk stratification. The emergence of discrete physiological measurements of high-density lipoprotein, such as cholesterol efflux capacity and the high-density lipoprotein inflammatory index, may provide an opportunity for clinical application in the future. However, the validity of these measurements and their commercial availability remain barriers to a realistic transition to clinical medicine.

Keywords

Cholesterol efflux capacity HDL function HDL inflammatory index high density lipoprotein cholesterol high density lipoprotein particle number atherosclerotic cardiovascular disease

Get full access to this article

View all access options for this article.

References

Benjamin

Virani

Callaway

et al.

Heart Disease and Stroke Statistics – 2018 update: a report from the American Heart Association. Circulation 2018; 137: e67–e492.

Castelli

Garrison

Wilson

et al.

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835–2838.

Mackey

Greenland

Goff

Jr et al.

High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012; 60: 508–516.

Di Angelantonio

Sarwar

Perry

et al.

Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993–2000.

Mora

Glynn

Ridker

. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013; 128: 1189–1197.

Parish

Offer

Clarke

et al.

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012; 125: 2469–2478.

Boden

Probstfield

Anderson

et al.

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255–2267.

Landray

Haynes

Hopewell

et al.

Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203–212.

Barter

Caulfield

Eriksson

et al.

Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109–2122.

10.

Schwartz

Olsson

Abt

et al.

Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089–2099.

11.

Lincoff

Nicholls

Riesmeyer

et al.

Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017; 376: 1933–1942.

12.

Shahid

Sun

Liu

et al.

Is high high-density lipoprotein cholesterol beneficial for premature coronary heart disease? A meta-analysis. Eur J Prev Cardiol 2016; 23: 704–713.

13.

2013 ACC/AHA Guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 2014; 63: 2935–2959.

14.

Acharjee

Boden

Hartigan

et al.

Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol 2013; 62: 1826–1833.

15.

Barter

Gotto

LaRosa

et al.

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301–1310.

16.

Hausenloy

Yellon

. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008; 94: 706–714.

17.

The HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017; 377: 1217–1227.

18.

Baigent

Blackwell

Emberson

et al.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.

19.

Krishna

Gheyas

Liu

et al.

Chronic Administration of anacetrapib is associated with accumulation in adipose and slow elimination. Clin Pharmacol Ther 2017; 102: 832–840.

20.

Keene

Price

Shun-Shin

et al.

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014; 349: g4379–g4379.

21.

Voight

Peloso

Orho-Melander

et al.

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380: 572–580.

22.

Rosenson

Brewer

Jr Barter

et al.

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nat Rev Cardiol 2018; 15: 9–19.

23.

Johannsen

Frikke-Schmidt

Schou

et al.

Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol 2012; 60: 2041–2048.

24.

Ference

Kastelein

JJP

Ginsberg

et al.

Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 2017; 318: 947–956.

25.

Tardif

Rheaume

Lemieux Perreault

et al.

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015; 8: 372–382.

26.

Tardif

Rhainds

Rheaume

et al.

CETP: Pharmacogenomics-based response to the CETP inhibitor dalcetrapib. Arterioscler Thromb Vasc Biol 2017; 37: 396–400.

27.

Jeyarajah

Cromwell

Otvos

. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26: 847–870.

28.

Huang

Silva

Jerome

et al.

Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011; 18: 416–422.

29.

Khera

Demler

Adelman

et al.

Cholesterol efflux capacity, HDL particle number, and incident cardiovascular events. An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation 2017; 135: 2494–2504.

30.

Ronsein

Hutchins

Isquith

et al.

Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects. Arterioscler Thromb Vasc Biol 2016; 36: 404–411.

31.

Masana

Cabre

Heras

et al.

Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis 2015; 238: 213–219.

32.

Tall

. An overview of reverse cholesterol transport. Eur Heart J 1998; 19(Suppl. A): A31–A35.

33.

deGoma

Rader

. Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51: 2199–2211.

34.

Rader

Alexander

Weibel

et al.

The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009; 50(Suppl.): S189–S194.

35.

Khera

Cuchel

de la Llera-Moya

et al.

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127–135.

36.

Rohatgi

Khera

Berry

et al.

HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014; 371: 2383–2393.

37.

Patel

Khera

Wilensky

et al.

Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail 2013; 15: 1215–1219.

38.

Ogura

Hori

Harada-Shiba

. Association between cholesterol efflux capacity and atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2016; 36: 181–188.

39.

Nicholls

Ruotolo

Brewer

et al.

Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol 2015; 66: 2201–2210.

40.

Tardif

Rhainds

Brodeur

et al.

Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes. Circ Cardiovasc Genet 2016; 9: 340–348.

41.

Bailey

Jahagirdar

Gordon

et al.

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010; 55: 2580–2589.

42.

Nicholls

Ray

Johansson

et al.

Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs 2018; 18: 109–115.

43.

Michael Gibson

Korjian

Tricoci

et al.

Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation 2016; 134: 1918–1930.

44.

Connelly

Shalaurova

Otvos

. High-density lipoprotein and inflammation in cardiovascular disease. Transl Res 2016; 173: 7–18.

45.

Rosenson

Brewer

Jr Ansell

et al.

Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 2016; 13: 48–60.

46.

Berliner

Navab

Fogelman

et al.

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488–2496.

47.

Zerrad-Saadi

Therond

Chantepie

et al.

HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2009; 29: 2169–2175.

48.

Huang

Riwanto

et al.

Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013; 123: 3815–3828.

49.

Mertens

Verhamme

Bielicki

et al.

Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003; 107: 1640–1646.

50.

Brennan

M-L

Penn

Van Lente

et al.

Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595–1604.

51.

Ansell

Navab

Hama

et al.

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751–2756.

52.

Patel

Khera

Jafri

et al.

The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 2011; 58: 2068–2075.

53.

Honda

Ueda

Kojima

et al.

Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 2012; 220: 493–501.

54.

Catapano

Pirillo

Bonacina

et al.

HDL in innate and adaptive immunity. Cardiovasc Res 2014; 103: 372–383.

55.

Lekkou

Mouzaki

Siagris

et al.

Serum lipid profile, cytokine production, and clinical outcome in patients with severe sepsis. J Crit Care 2014; 29: 723–727.

56.

Madsen

Varbo

Tybjaerg-Hansen

et al.

U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies. Eur Heart J 2018; 39: 1181–1190.

57.

Mineo

Deguchi

Griffin

et al.

Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352–1364.

58.

Riwanto

Rohrer

Roschitzki

et al.

Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013; 127: 891–904.

59.

Sumi

Sata

Miura

et al.

Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 813–818.